Scientific Sessions 2025  /  When the Left Heart Goes Bad: Pulmonary Hypertension Due to Left Heart Disease  /  Beyond HFpEF: PH in Other Cardiomyopathies
Logo

American Heart Association

  46
  0

Final ID:

Beyond HFpEF: PH in Other Cardiomyopathies

  • Rosenkranz, Stephan  ( University of Cologne Heart Center , Cologne , Germany )
  • Maron, Brad  ( University of Maryland , Sharon , Massachusetts , United States )
  • Simon, Marc  ( UCSF , San Francisco , California , United States )
    • Author Disclosures:
    Stephan Rosenkranz: DO have relevant financial relationships ; Consultant:Gossamer:Past (completed) ; Speaker:United Therapeutics :Active (exists now) ; Speaker:BMS:Active (exists now) ; Speaker:Bayer:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:AOP:Active (exists now) ; Speaker:Janssen:Active (exists now) ; Speaker:Actelion:Active (exists now) ; Speaker:MSD:Active (exists now) ; Speaker:Abbott:Active (exists now) ; Research Funding (PI or named investigator):MSD:Active (exists now) ; Speaker:Ferrer:Active (exists now) ; Research Funding (PI or named investigator):Janssen:Active (exists now) ; Research Funding (PI or named investigator):Bayer:Past (completed) ; Research Funding (PI or named investigator):AstraZeneca:Active (exists now) | Brad Maron: DO NOT have relevant financial relationships | Marc Simon: DO have relevant financial relationships ; Consultant:Janssen:Past (completed) ; Consultant:Tenax:Expected (by end of conference) ; Consultant:Gossamer Bio:Past (completed) ; Consultant:Merck:Past (completed) ; Consultant:Aerovate:Past (completed)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

When the Left Heart Goes Bad: Pulmonary Hypertension Due to Left Heart Disease

Monday, 11/10/2025 , 01:30PM - 02:45PM

Cardiovascular Seminar

More abstracts on this topic:
Debate - Most Patients With CpcPH and RV Dysfunction Should Receive PAH-Targeted Therapies

Thenappan Thenappan, Ghio Stefano, Forfia Paul

Debate - Most Patients With CpcPH and RV Dysfunction Should NOT Receive PAH-Targeted Therapies

Maron Brad, Gomberg-maitland Mardi, Hemnes Anna, De Marco Teresa

More abstracts from these authors:
RV in extremis

Maron Brad

Panel Discussion

Maron Brad

You have to be authorized to contact abstract author. Please, Login
Not Available